# Recursion Pharmaceuticals, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Recursion Pharmaceuticals, Inc). ## Overview Recursion Pharmaceuticals is a U.S.-based clinical-stage TechBio company that uses its Recursion Operating System to discover and develop medicines. Its business combines an internal pipeline of drug candidates with strategic partnerships, using AI, multimodal biological data, and automated chemistry to move from biological insight to clinical development. ## Products & services • Internal drug discovery and development programs • AI-native Recursion Operating System (Recursion OS) • Partnered drug discovery collaborations • Multimodal biological data generation and analysis • Small-molecule synthesis and clinical development support - **Internal therapeutic programs** (35%) — Wholly owned drug candidates advancing through discovery and clinical development. - **Strategic collaborations** (45%) — Research and development agreements with pharmaceutical and biotech partners. - **Recursion OS platform services** (20%) — AI-enabled discovery, data generation, and development capabilities used internally and for partners. - Internal drug discovery and development programs - AI-native Recursion Operating System (Recursion OS) - Partnered drug discovery collaborations - Multimodal biological data generation and analysis - Small-molecule synthesis and clinical development support ## Customers Recursion’s customers are primarily pharmaceutical, biotechnology, and research partners that pay for discovery and development work under collaboration agreements. The company also serves future end-markets indirectly through its own pipeline, which targets patients in oncology and rare disease once programs advance to commercialization. - **Pharmaceutical collaboration partners** (primary) — Large pharma companies buy discovery and development services, data, and program work through alliance agreements. - **Biotechnology partners** (primary) — Biotech companies use Recursion's platform and scientific capabilities to accelerate target discovery and candidate generation. - **Academic and research institutions** (secondary) — Institutions collaborate for access to datasets, biology expertise, and intellectual property. - **Future therapeutic end users** (emerging) — Patients and healthcare systems are the eventual end market for approved medicines from the internal pipeline. - Pharmaceutical partners funding discovery and development collaborations - Biotech partners seeking AI-enabled drug discovery capabilities - Academic and research collaborators accessing datasets or IP - Future patients in oncology and rare disease targeted by internal programs - Potential commercial partners for approved drug candidates ## Geography Recursion is headquartered in the United States, with operations and collaboration activity spanning North America and Europe. The company also maintains research sites in Montréal and London, which support its AI and computational biology capabilities and broaden access to scientific talent. - United States is the headquarters and core operating base - Montréal site houses Valence Labs, the AI research engine - London office supports European AI and computational talent - Collaborations can generate revenue across multiple geographies - Clinical and commercialization plans may extend beyond the U.S. ## Strategy Recursion’s strategy is to use its integrated AI-native platform to increase the speed and quality of drug discovery, while validating the platform through both internal programs and partner collaborations. The company is building a diversified pipeline across oncology and rare disease, with partnerships serving as external proof points for the Recursion OS. - **Advance wholly owned clinical programs** (short-term) — Clinical data is the main value driver for a TechBio pipeline and validates the platform. - **Scale the Recursion OS platform** (medium-term) — A stronger platform improves candidate selection, reduces attrition, and supports partner demand. - **Deepen strategic partnerships** (medium-term) — Collaborations provide non-dilutive funding, external validation, and broader data access. - Advance internal pipeline programs to clinical proof of concept - Use partnerships to validate the Recursion OS platform - Expand multimodal data and AI capabilities across R&D - Pursue small-molecule programs in oncology and rare disease - Retain commercial optionality for approved candidates ## Risks Recursion faces the typical risks of a clinical-stage biotechnology company: no approved products, long development timelines, and dependence on external capital and collaboration revenue. Its platform model also depends on third-party vendors, data quality, and successful translation of AI-driven discovery into clinical outcomes. - **Clinical development failure** [high] — Drug candidates can fail in discovery, preclinical work, or clinical trials, which would reduce pipeline value. - **Capital dependence** [high] — The company has no approved product sales and relies on financing and collaboration receipts to fund operations. - **Partner concentration and milestone timing** [medium] — Collaboration revenue is tied to performance obligations and milestone achievement, which can be uneven. - **Supply chain and manufacturing dependence** [medium] — The company relies on third-party CDMOs, vendors, and testing providers for drug substance and product. - **Technology and data execution risk** [high] — The Recursion OS must consistently generate useful biological insight and candidate selection to justify the model. - No approved products, so value depends on clinical and regulatory success - Needs additional capital to fund development and future commercialization - Revenue depends on milestone timing and partner performance obligations - Third-party manufacturing and suppliers create supply chain exposure - AI-driven discovery may not translate into successful medicines ## Accounting The most important accounting issue is revenue recognition for collaboration agreements, where revenue is tied to performance obligations and milestone timing rather than cash receipts. Investors should also watch stock-based compensation, acquisition-related accounting, and estimates around R&D and intangible assets, because these can materially affect reported losses and comparability across periods. - **Revenue recognition for collaborations** — Affects operating revenue and quarter-to-quarter comparability - **Milestone-based consideration** — Can create lumpy revenue recognition - **Stock-based compensation** — Affects reported R&D and G&A expense - **Acquisition-related accounting** — Can distort year-over-year comparisons - Collaboration revenue depends on milestone and performance obligation timing - Cash receipts may not match recognized revenue in a given period - R&D expense reflects heavy use of external vendors and internal labor - Stock-based compensation can materially affect operating expense - Acquisition accounting may change revenue and cost comparability --- *Last updated: 2026-09-24T12:09:10.473499+00:00*